For patients with unresectable very early to early-stage hepatocellular carcinoma with suboptimal location for ablation, radiation segmentectomy is efficacious with few high-grade adverse events.
Investigators assessed the safety and efficacy of immunotherapy with nivolumab alone or in combination with ipilimumab in patients with resectable hepatocellular carcinoma.
Investigators assessed the safety and efficacy of neoadjuvant cemiplimab for treatment of patients with early-stage, resectable hepatocellular carcinoma.
Investigators assessed trends and patterns of healthcare spending in patients with GI malignancies in the US and predicted spending estimates for the next decade.
Investigators assessed long term outcomes of treatment with radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.
Elevated serum iron and transferrin saturation levels are significantly associated with an increased risk for developing liver cancer in patients with NAFLD.
Investigators aimed to determine the potential correlation between weight loss medications and the development of cirrhosis and HCC among individuals with obesity.
Investigators evaluated the antitumor activity of infigratinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 alterations.
Investigators assessed the benefit of a potential living donor on survival in patients with hepatocellular carcinoma on a waiting list for a liver transplant.
Investigators assessed the cardiac-specific mortality rate among patients with major GI cancers, as well as the relationship between radiation and chemotherapy with survival outcomes.
In a post-hoc analysis, researchers assessed the effects of lenvatinib compared with sorafenib on health-related quality of life in patients with hepatocellular carcinoma.
Researchers aimed to validate use of the NCYA score and its incorporation of AFP-R in the selection of patients for liver transplant due to HCC recurrence.
